Healthcare
RDNT’s AI narrative is materially overhyped relative to fundamentals. The AI business remains nascent, loss-making and largely unreimbursed, with equipment vendors increasingly bundling AI into imaging hardware, eroding RDNT’s perceived edge. Meanwhile, the core business remains highly capital intensive: imaging equipment is costly and capex has consumed ~50% of EBITDA for several years. Lately, that is 10% of sales in a mid-teens margin business, more than twice that of Two Rivers’ selected comp group. Operating leverage is limited as labour, equipment and supply costs continue to rise. While RDNT has reduced its leverage, it is still a concern at 4.4x forward EBITDA. The stock is priced to perfection, trading at all-time high EV/Sales, EV/EBITDA and earnings multiples. It has historically traded at a 40-50% EBITDA multiple discount to the comps - now it trades on par with them.
Edition: 229
- 06 February, 2026
Healthcare
Tom Tobin thinks there are several secular trends, including AI tailwinds, which makes RDNT a compelling idea even after its share price has rebounded in recent months. Core to Tom’s thesis is his ability to track Diagnostic Radiology staffing at RDNT, monitor turnover, and forecast volume and revenue per clinician. While the current valuation against consensus estimates appears stretched, he can model upside well into 2027 with a number of simultaneous secular tailwinds that justify the premium: 1) continued inpatient-to-outpatient imaging migration; 2) mix shift towards high-margin advanced imaging where demand is being driven by Alzheimer's, Oncology and Cardiology; and 3) AI tailwinds driving incremental revenue and operating leverage.
Edition: 225
- 28 November, 2025
Healthcare
Declining reimbursement rates coupled with rising expenses looks set to weigh on margins - earnings shortfalls should cause investors to rethink RDNT’s AI-inflated multiples. Medical imaging, notably core MRI reimbursement rates, are declining at CAGRs of 5-6%. All major operating expenses are rising, competition is increasing and capex requirements are high and ongoing. RDNT is also highly levered (5.5x trailing EBITDA). The stock is up >90% YTD and trades at nearly all-time high EV/Sales, EV/EBITDA and earnings multiples. Historically, it traded at a 40-50% EBITDA multiple discount to competitors, now it trades on par with them.
Edition: 176
- 22 December, 2023